San Diego, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical biopharmaceutical company focused on developing proprietary molecules with strong clinical and commercial differentiation, announced the publication of a peer-reviewed paper reporting that THCVHS, the Company’s novel THC prodrug, was optimized through a nanoemulsion formulation (THCVHS-NE) for drug delivery into the eye and demonstrated significantly better reduction of intraocular pressure (IOP) compared to the commercially approved standard of care in normotensive rabbits.